Aminoven® Infant 10%

Aminoven Infant 10%

Amino acid solution for parenteral nutrition of pediatric patients


  1. An amino acid solution for parenteral nutrition of preterm & term newborns, babies , infants and young children
  2. Excellent nutritional efficacy for growth and development, with high tolerance and safety.
  3. Contains a well balanced amino acids pattern with:
  • 52% essential amino acids
  • Taurine which is an essential nutrient for neonates
  • Cysteine & tyrosine that are not synthesized in sufficient amounts
  • Low contents of methionine & phenylalanine due to their limited degradation rate

 4.  Further there is no risk of metabolic acidosis and no risk of allergic reactions


Designed to meet special amino acid requirement of pediatric patients which are characterized by

  •  High need for essential amino acids to ensure normal growth
  •  Metabolic immaturity
  •  Taurine is essential for retinal development
  •  Taurine also enhance  bile acid / bile acid flow, thus reducing hepatic insufficiency and cholestasis
  •  Low capacity to compensate for metabolic inadequate amino acid intake


  • For partial parenteral nutrition of infants (preterm and term  newborns, babies) and young Children.             
  • May serve as part of total parenteral nutrition together with carbohydrates and fat as energy source, and vitamins, electrolytes and trace elements

Packaging / Dosage

10%,100 ml bottle

Age of 1 yr:

1.5 – 2.5 g amino acids/kg body wt

= 15 -25 ml/ kg body wt

Age of 2-5 yrs:

1.5 g amino acids/kg body wt

=15 ml/kg body wt

 Age of 6-14yrs:

1.0 g amino acids/kg body wt

=10 ml/kg body wt

Product Information


Aminoven Infant

AA gms










Total Nitrogen (g/l/pack)


NPE Kcals


Total Kcals


Osmolarity (mosmol/L)


Infusion Rate

2-10 drops/min

Max.Dosage (ml/kg/day)


Shelf life (months)


Route of Adm





  1. Rino J. Senterre J; Is taurine essential for the neonates ?  Biol Neonate 1977;32:73-6
  2. Kender BS. Taurine: An overview of its role in preventative medicine. Preventative Medicine 1989; 1:79-100
  3. Tyson JE, Lasky R, Flood D, Mize C, Picone T, Paule CL: Randomized trial of taurine supplementation  for infants ≤1,300-gram birth weight: effect on auditory brainstem-evoked responses. Pediatrics 1989;83:406.
  4. Geggel HS. Amend ME, Heckenlively JR. Martin DE, Kopple JD: Nutritional requirement for taurine in patients receiving long-term parenteral nutrition. N. Engl J Med 1985; 312:142-146
  5. Oja, SS Kontro P. Taurine: In Handbook of Neurochemistry. 2nd ed. (A. Lajtha. Ed.)Vol.3.Plenum, New York, 1983. pp501
  6. Sturman JA, Gaull GE: Taurine in the brain and liver of the developing human and monkey. J. Neurochem1975;25:831-835
  7. Sebring L, Huxtable RJ:Taurine modulation of calcium binding to cardiac sarcolemma.J.Pharmacol.Exp.Therap 1985; 232:445-451
  8. Bernardi N: On the role of taurine in the cerebellar cortex: Area-ppraisal, Acta Physiol. Pharmacol. Latinoamer 1985;35:153-164
  9. Cooper A, Betts JM, Periera GR: Taurine deficiency in the severe hepatic dysfunction complicating total parenteral nutrition. J Pediatr Surg 1984;19:462
  10. Meehan JJ, Georgeson KE: Prevention of liver failure in parenteral nutrition-dependent children with short bowel syndrome. J Pediatr Surg 1997;32:473-475
  11. Emudianughe TS, Caldwell J. Smith RL: The utilization of exogenous taurine for the conjugation of xenobiotic acids in the ferret. Xenobiotica 1983;13:133-138
  12. Sturman JA:Taurine in development. J Nutr 1988;118:1169
  13. Gaull GE, Wright CE, Tallan HH: Taurine in human lymphoblastoid cells: uptake and role in proliferation. In Sulfur Amino Acids: Biochemical and Clinical Aspects (Kuriyama RJ. Huxtable and H. Iwata Eds.). A.R. Liss, New York, 1983. pp297
  14. Pasantes-Morales H, Wright CE, Gaull GE: Taurine protection of lymphoblastoid cells from iron-ascorbate-induced damage.  Biochem. Pharmacol 1985;34:2205-2207
  15. Wright GE. Tallan HH, Lin YY: Taurine Biological update. Annu. Rev. Biochem 1985;55:427-453
  16. Thursten JH, Hauhart RE, Dirgo JA: Taurine: A role in osmotic regulation of mammalian brain and possible clinical significance Life Sci 1980;26:1561-1568.
  17. Redmont HP, Stapleton PP, Nearly P, Bouchier-Hayes D: Immuno-nutrition: the role of taurine. Nutrition 1998; 14:599-604
  18. Howard D, Thompson DF: Taurine: an essential amino acid to prevent cholestasis in neonates? Ann Pharmacother 1992; 26:139
  19. Guertin F, Roy CC, Lepage G, Perea A, Giguere R, Yousef I, Tuchweber B: Effect of taurine on total parenteral nutrition-associated cholestasis. JPEN 1991; 15:247-251
  20. Hofmann AF, and Small DM: Detergent properties of bile salts: Correlation with physiological function. Anne Rev. Med 1967; 18:333-376
  21. Stratman C, Goebel HJ, Abel M. Holzki J: Taurine in the new born and infant undergoing surgery. Adv. Exp Med Biol 1995;359:411-2
  22. Teitelbaum DH, Cora AG: Perioperative nutritional support in pediatrics. Nutrition 1998; 14:130-142
  23. Zlotkin SH, Bryan MH, Anderson GH: Cysteine supplemenatation to cysteine free intravenous feeding regimens in newborn infants. AM J Clin Nutr 1981b;43:914
  24. Zoltkin SH, Anderson SH: The development of cystathionase activity during the first year of life. Pediatr Res 1982; 16:65
  25. Clark SE, Karn CA, Ahlrichs JA, Wang J, Leitch CA, Liechty EA, Denne SC: Acute changes is leucine and phenylalanine kinetics produced by parenteral nutrition in premature infants. Pediatr Res 1997;41:568-574
  26. Phase III clinical Trial: Aminoven ®Infant 10%, Fresenius Kabi GmbH, unpublished data 1994
  27. Castillo L, Yu YM, Marchini JS, Chapman TE, Sanchez M, Young VR, Burke JF: Phenylalanine and tyrosine kinetics in critically ill children with sepsis. Pediatr Res 1994;35:580-588
  28. Roberts SA, Ball RO, Filler, RM , Moore AM, Pencharz PB: Phenylalanine and tyrosine metabolism in neonates receiving parenteral nutrition differing in pattern of amino acids, Pediatr Res 1998;44:907-91